Numerous pain-producing (pronociceptive) receptors signal via phosphatidylinositol 4,5-bisphosphate (PIP 2 ) hydrolysis. However, it is currently unknown which lipid kinases generate PIP 2 in nociceptive dorsal root ganglia (DRG) neurons and if these kinases regulate pronociceptive receptor signaling. Here, we found that phosphatidylinositol 4-phosphate 5 kinase type 1C (PIP5K1C) is expressed at higher levels than any other PIP5K and, based on experiments with Pip5k1c +/À mice, generates at least half of all PIP 2 in DRG neurons. Additionally, Pip5k1c haploinsufficiency reduces pronociceptive receptor signaling and TRPV1 sensitization in DRG neurons as well as thermal and mechanical hypersensitivity in mouse models of chronic pain. We identified a small molecule inhibitor of PIP5K1C (UNC3230) in a highthroughput screen. UNC3230 lowered PIP 2 levels in DRG neurons and attenuated hypersensitivity when administered intrathecally or into the hindpaw. Our studies reveal that PIP5K1C regulates PIP 2 -dependent nociceptive signaling and suggest that PIP5K1C is a therapeutic target for chronic pain.
INTRODUCTION
Tissue inflammation and nerve injury cause the release of a complex mix of chemicals that sensitize nociceptive dorsal root ganglia (DRG) neurons and contribute to chronic pain (Basbaum et al., 2009 ). These chemicals activate molecularly diverse pronociceptive receptors found on DRG neurons and their axon terminals. While these receptors represent attractive targets for analgesic drug development, efforts to block individual pronociceptive receptors have not yet produced effective treatments for chronic pain (Gold and Gebhart, 2010) . This lack of efficacy could reflect the fact that multiple pronociceptive receptors are activated in the setting of chronic pain.
One approach to treat pain that bypasses this receptor diversity is to target points where different signaling pathways converge. Indeed, drugs that block signaling proteins that are several steps downstream from receptor activation, including protein kinase Cε (PKCε) and mitogen-activated protein kinases (MAPKs), reduce nociceptive neuron sensitization, thermal hyperalgesia, and mechanical allodynia in animal models (Aley et al., 2000 (Aley et al., , 2001 Cesare et al., 1999; Cheng and Ji, 2008; Dai et al., 2002; Ji et al., 2002 Ji et al., , 2009 ). However, drugs that inhibit PKCε or MAPKs have shown modest-to-no efficacy in treating different pain conditions in humans (Anand et al., 2011; Cousins et al., 2013; Ostenfeld et al., 2013; Tong et al., 2012) . This limited efficacy does not mean that PKCε or MAPK inhibitors cannot be used to treat pain, as drugs can show limited-to-no efficacy for a number of reasons, including the drugs may not engage their molecular target in humans or the drugs may lack efficacy in some pain conditions but not others.
Another convergence point, albeit one that has not been fully explored in the context of treating pain, is immediately downstream of multiple pronociceptive receptors. Many pronociceptive receptors, including Gq-coupled receptors, Gs-coupled receptors (via EPAC), and receptor tyrosine kinases, initiate signaling upon phospholipase C (PLC)-mediated hydrolysis of the lipid second messenger PIP 2 (Hucho et al., 2005) . PIP 2 hydrolysis produces diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP 3 ), which regulate nociceptive sensitization via multiple pathways, including PKC-dependent modulation of ion channels like TRPV1, MAPK activation, and IP 3 -mediated calcium influx (Falkenburger et al., 2010; Gamper and Shapiro, 2007; Gold and Gebhart, 2010; Rohacs et al., 2008; Tappe-Theodor et al., 2012) . PIP 2 thus sits at a convergence point for diverse receptors and signaling pathways that promote and maintain nociceptive sensitization. In light of this information, we reasoned that it might be possible to reduce signaling through pronociceptive receptors and reduce pain sensitization by inhibiting the lipid kinase that generates the majority of all PIP 2 in DRG neurons.
Type 1 phosphatidylinositol 4-phosphate 5-kinases (Pip5k1s) generate PIP 2 by phosphorylating the 5 position on the inositol ring of phosphatidylinositol 4-phosphate [PI(4)P]. There are three mammalian Pip5k1 genes (Pip5k1a, Pip5k1b, and Pip5k1c) (Ishihara et al., 1998) . Of these, Pip5k1c (also known as Pip5k1g) is highly expressed in the brain (Wenk et al., 2001) . PIP5K1C regulates receptor-mediated calcium signaling, actin cytoskeletal dynamics, endocytosis, and exocytosis (Di Paolo et al., 2004; Legate et al., 2012; Ling et al., 2002; Unoki et al., 2012; van den Bout and Divecha, 2009; Vasudevan et al., 2009; VolpicelliDaley et al., 2010; Wang et al., 2004 Wang et al., , 2007 Xu et al., 2010; Yu et al., 2011) .
Previous studies examined the functions of Pip5k1c in the brain of knockout mice (Di Paolo et al., 2004; Rodriguez et al., 2012; Volpicelli-Daley et al., 2010; White et al., 2013) . Homozygous (Pip5k1c À/À ) knockout mice have $50% less PIP 2 in their brains and die within 24 hr of birth due to impaired mobility and an inability to feed (Di Paolo et al., 2004; White et al., 2013) . These data suggest a critical role for PIP5K1C in generating PIP 2 in neurons and in nervous system development. In contrast, heterozygous (Pip5k1c +/À ) mice are viable, reproduce normally, have normal levels of PIP 2 in the brain and showed no phenotypes in an extensive battery of tests, including multiple tests of neurological function (Di Paolo et al., 2004; White et al., 2013) . The only phenotype observed thus far in Pip5k1c +/À mice is high-frequency (>20 kHz) hearing loss (Rodriguez et al., 2012) , a phenotype ascribed to Pip5k1c haploinsufficiency in nonsensory cells of the auditory system. Figure S1 .
When we initiated our studies, it was unknown which enzymes generated PIP 2 in nociceptive DRG neurons or if these enzymes regulated nociception. Here, we report that PIP5K1C is expressed in nearly all DRG neurons, generates at least half of all PIP 2 in the DRG, and regulates nociceptive sensitization in response to diverse stimuli that cause pain. Our studies validate PIP5K1C as an analgesic drug target and identify a PIP5K1C inhibitor that attenuates pain in animal models.
RESULTS

PIP5K1C
Generates at Least Half of All PIP 2 in DRG Neurons To determine which Pip5k1s were expressed in the DRG, we performed in situ hybridization with probes for the three known mammalian Pip5k1 genes. We found that Pip5k1c was expressed at higher levels in adult mouse DRG than the two other Pip5k1 genes and was expressed in nearly all DRG neurons . PIP5K1C is also present in the brain at higher levels than PIP5K1A and PIP5K1B (Akiba et al., 2002; Wenk et al., 2001) . Consistent with widespread expression in all DRG neurons, based on in situ hybridization, Pip5k1c was expressed in virtually all peptidergic (96.7%; n = 220 counted) and nonpeptidergic (96.1%; n = 210 counted) nociceptive neurons, marked by Calcitonin gene-related peptide-alpha (Cgrp) and Prostatic acid phosphatase (Pap), respectively ( Figures 1D and 1E ) (McCoy et al., 2013; Zylka et al., 2008) . Using a recently developed antibody (Hara et al., 2013) , we found that PIP5K1C was present on the plasma membrane and in the cytoplasm of most DRG neurons (Figures S1A-S1C available online). PIP5K1C was highly colocalized with PAP (98.1%; n = 2,672 counted), CGRP (97.5%; n = 2,094 counted), and TRPV1 (92.2%; n = 1,915 counted), markers of nociceptive neurons (Figures S1D-S1L). Moreover, PIP5K1C was expressed in human DRG at levels comparable to CGRP (intensity values of 311 and 346, respectively, from Affymetrix GeneChip experiments).
We then quantified PIP5K1C protein and PIP 2 levels in the DRG of wild-type (WT; Pip5k1c +/+ ), Pip5k1c +/À , and Pip5k1c
embryonic (E17.5-E18.5) mice. We found that PIP5K1C protein and PIP 2 levels were reduced (by $50%) in the DRG of Pip5k1c +/À embryonic mice ( Figures 1F-1H ). No PIP5K1C protein was detectable in DRG from Pip5k1c À/À embryonic mice, confirming complete gene knockout and that both antibodies used in our study specifically recognized PIP5K1C ( Figures 1F  and 1G ). In addition, PIP 2 was reduced by $70% in DRG from Pip5k1c À/À embryonic mice ( Figure 1H ).
Unlike Pip5k1c À/À mice that die at birth, Pip5k1c +/À mice live into adulthood and reproduce normally (Di Paolo et al., 2004) . Therefore, we quantified PIP5K1C protein and PIP 2 levels in the DRG from Pip5k1c +/À adult mice and WT littermate controls.
PIP5K1C protein was reduced by $40% and PIP 2 levels were reduced by $50% in the DRG of Pip5k1c +/À mice ( Figures 1I  and 1K ). In contrast, PIP 2 was not reduced in spinal cord or brain from adult Pip5k1c +/À mice ( Figure 1K ). Likewise, using a different quantification method, PIP 2 was not reduced in the brain of embryonic Pip5k1c +/À mice (Di Paolo et al., 2004; Volpicelli-Daley et al., 2010) . In addition, we used immunofluorescence staining to examine PIP 2 levels at the membrane of cultured DRG neurons taken from adult mice. Quantification of the average perimeter (membrane) staining intensity in confocal images revealed that membrane PIP 2 levels were reduced by $50% in small-to-medium diameter (%27 mm) neurons of Pip5k1c +/À mice compared to WT controls ( Figures 1L and   1M 2+ influx in small-to-medium diameter DRG neurons and, when injected intrathecally (i.t.), produces a chemically-induced form of neuropathic pain that is dependent on LPA1 receptor activation (Elmes et al., 2004; Inoue et al., 2004) . 17-PT PGE 2 is a selective agonist for G q -coupled prostanoid receptors, a class of receptors that are implicated in pain hypersensitivity following inflammation (Kassuya et al., 2007; Minami et al., 1994 +/À cultures (data not shown). We also found that delivering excess PIP 2 to WT neurons did not elevate LPA-or 17-PT PGE 2 -evoked calcium responses beyond control levels, suggesting that PIP 2 levels are already saturated in WT neurons under our culture conditions. Collectively, our data reveal that PIP5K1C regulates signaling downstream from two pronociceptive receptors, one associated with neuropathic pain and the other with inflammatory pain. Moreover, rescue experiments revealed that Pip5k1c regulates calcium signaling in DRG neurons via a PIP 2 -dependent mechanism, placing PIP5K1C upstream of multiple signaling pathways implicated in pain sensitization ( Figure 2E ).
Pip5k1c
Haploinsufficiency Reduces Ligand-Induced Nocifensive Behaviors LPA and 17-PT PGE 2 induce GPCR-mediated nociceptive responses when injected into the hindpaw (Kassuya et al., 2007; Renbä ck et al., 1999 Renbä ck et al., , 2000 . To determine if these compounds signal less effectively in Pip5k1c +/À mice, we injected LPA (4.1 mg) or 17-PT PGE 2 (1.2 mg) into one hindpaw then monitored the duration of licking for 5 min. We found that Pip5k1c +/À mice spent less time licking their ligand-injected hindpaws when compared to WT littermates ( Figure 2F ). Reduced licking was not due to motor impairment, as there were no significant differences between WT and Pip5k1c +/À mice in the rotarod assay and gait was not impaired (stride or stance; Figures S2A-S2C ). Moreover, acute responses to innocuous mechanical touch were not impaired in Pip5k1c +/À mice ( Figure S2D ).
There was also no loss of nociceptive neurons or terminals in spinal cord of Pip5k1c +/À mice (determined by immunostaining for CGRP and IB4-binding, markers of nociceptive neurons; Figures S3A-S3J ). Excitatory synaptic transmission between sensory neurons and spinal dorsal horn neurons was not impaired in Pip5k1c +/À mice, assessed by measuring excitatory field potential (fEPSP) amplitude in spinal cord slices after stimulating the dorsal root with a suction electrode (Street et al., 2011) . Specifically, we found no significant differences between genotypes in fEPSP amplitude at different stimulus strengths ( Figure S3K ), following synaptic depletion (Figures S3L and S3M) or during synaptic recovery ( Figure S3N ). These data also ruled out the possibility that synaptic transmission or synaptic vesicle trafficking was impaired in Pip5k1c +/À mice. Instead, our data suggest that reduced nocifensive licking in Pip5k1c
reflects reduced pronociceptive receptor activation in vivo.
Pip5k1c Haploinsufficiency Attenuates TRPV1 Activation and Sensitization PIP 2 levels also affect the activity and sensitization of the capsaicin and noxious heat receptor TRPV1 (Lukacs et al., 2007; Rohacs et al., 2008) . To determine if Pip5k1c haploinsufficiency affected TRPV1 activation, we stimulated cultured DRG neurons from WT and Pip5k1c +/À mice with a high concentration of capsaicin (1 mM) then monitored calcium responses. We found that capsaicin-evoked calcium responses were blunted in DRG neurons from Pip5k1c +/À mice ( Figure 3A ) and that addition of exogenous PIP 2 to Pip5k1c +/À neurons restored capsaicin- evoked calcium responses to WT levels ( Figures 3A and 3B ). These data are consistent with the literature showing that PIP 2 is required for full activity when TRPV1 is activated with a high concentration of capsaicin (Lukacs et al., 2007; Rohacs et al., 2008) . To evaluate TRPV1 sensitization by a GPCR agonist, we stimulated DRG neurons with a submaximal capsaicin concentration (100 nM; to limit the effects of Ca 2+ -induced desensitization), applied the GPCR agonist LPA (1 mM), and then stimulated with capsaicin again to assess TRPV1 activity. We found that LPA sensitized TRPV1 activity in neurons cultured from WT mice (AUC value increased from 6.3 ± 1.5 to 8.9 ± 1.5; unpaired t test, p < 0.05) ( Figure 3C ). In contrast, LPA failed to sensitize TRPV1 in neurons cultured from Pip5k1c +/À mice (AUC value decreased from 8.8 ± 2.0 to 3.6 ± 0.7; suggesting TRPV1 was desensitized) ( Figure 3C ). This likely reflected normal desensitization of TRPV1 caused by repeated capsaicin pulses (Loo et al., 2012) . Consistent with this possibility, we found that repeated application of capsaicin (without adding LPA) caused desensitization of TRPV1 (data not shown). There was no significant difference in AUC values between WT and Pip5k1c +/À neurons following the first application of this low (100 nM) dose of capsaicin, consistent with previous literature showing that TRPV1 activity is less affected by changes in PIP 2 levels at low capsaicin concentrations (Lukacs et al., 2007; Rohacs et al., 2008) .
Next, we evaluated how Pip5k1c haploinsufficiency affected TRPV1-mediated nociception in vivo. Injection of capsaicin (intraplantar) produced mechanical allodynia in WT mice but not thermal hyperalgesia ( Figure 3D , data not shown), consistent with a previous study (Gilchrist et al., 1996) . However, capsaicininduced mechanical allodynia was significantly blunted in Pip5k1c +/À mice ( Figure 3D ). Pip5k1c +/À mice also exhibited increased withdrawal latencies at 45 C, 50 C, and 55 C relative to WT mice in the restrained hot plate assay ( Figure 3E ). Taken together, these data suggest that Pip5k1c is required for appropriate activation and sensitization of TRPV1 and for normal responsiveness to noxious heat.
Pip5k1c Haploinsufficiency Impairs Thermal and Mechanical Sensitization in Models of Chronic Pain
Pronociceptive receptor activation can sensitize animals to noxious thermal and mechanical stimuli. Because pronociceptive receptors signaled less effectively in vitro and in vivo, we hypothesized that thermal and mechanical sensitization might be blunted in Pip5k1c +/À mice following inflammation or injury.
Indeed, thermal hyperalgesia and mechanical allodynia were enduringly attenuated in Pip5k1c +/À mice in models of chemically induced neuropathic pain (i.t. injection of 1 nmol LPA), neuropathic pain caused by spared-nerve ligation and inflammatory pain following an intraplantar injection of complete Freund's adjuvant (CFA) (Figures 4A-4F ). There were no significant differences in the contralateral (noninflamed/noninjured) paw between WT and Pip5k1c +/À mice, and there were no significant differences in either paw at baseline (prior to LPA injection, nerve injury, or inflammation). Taken together, these data suggest that Pip5k1c regulates nociceptive sensitization in three different models of chronic pain, with initiating events at three different anatomical locations (intrathecal, peripheral nerves, and hindpaw).
Identification of a Small Molecule PIP5K1C Inhibitor that Reduces Membrane PIP 2 Levels and Reduces Pronociceptive Receptor Signaling
At the time we began our study, there were no small molecule inhibitors of PIP5K1C or any other lipid kinase that directly (E and F) Thermal (E) and mechanical sensitivity (F) in CFA inflammatory pain model. CFA (20 ml) was injected into one hindpaw. Contralateral paw was not injected and served as a control. n = 10 male mice per genotype. All data are mean ± SEM. Asterisks indicate significant difference between WT and Pip5k1c +/À mice by a one-way ANOVA. *p < 0.05, **p < 0.005, ***p < 0.0005.
generates PIP 2 . Because small molecule inhibitors can provide a complimentary method to validate targets when compared to genetic methods and can establish target tractability for drug discovery efforts (Weiss et al., 2007) , we set out to identify a selective small molecule inhibitor of PIP5K1C. Accordingly, we developed a high-throughput microfluidic mobility shift assay that separates fluorescein conjugated PI(4)P (substrate) from fluorescein conjugated PIP 2 (product) (Figures 5A and 5B ). We used this assay to screen a kinase-focused library ($5,000 compounds) for inhibitors of recombinant human PIP5K1C (data not shown, assay development and screen will be described in a subsequent article; human and mouse PIP5K1C are 96% identical at the amino acid level within the kinase domain and 92% identical across the entire protein). From this screen, we identified UNC3230 [5-(cyclohexanecarboxamido)-2-(phenylamino) thiazole-4-carboxamide] that had an IC 50 of $41 nM using the microfluidic mobility shift assay ( Figure 5C ). To assess selectivity, we screened UNC3230 against 148 kinases (see Experimental Procedures), covering all major branches of the kinome ( Figure 5D ). Remarkably, UNC3230 inhibited (ProfilerPro assays) Figure S4 .
or competitively interacted (DiscoveRX binding assays) with only five other kinases at our relatively high (10 mM) screening concentration (using 10% activity/binding remaining relative to control as the cutoff for each kinase group, except lipid kinases, where a more stringent 35% of control cutoff was used) ( Figure 5D ; Table S1 ). Notably, UNC3230 did not interact with PIP5K1A at 10 mM, a PIP5K family member that is highly similar (69% amino acid identity across the entire protein and 82% identity within the kinase catalytic domain) to PIP5K1C. Based on dose-responses with the five kinases that were inhibited by UNC3230 at the 10 mM screening concentration, UNC3230 showed selectivity (K d < 0.2 mM; using competitive binding assays) for PIP5K1C and PIP4K2C (phosphatidylinositol 5-phosphate 4-kinase, type II, gamma) ( Figures  5E-5G ). PIP5K1C and PIP4K2C directly generate PIP 2 , albeit using different substrates; PI(4)P versus PI(5)P, respectively (Figure S4 ). UNC3230 represents a selective inhibitor for these lipid kinases. Moreover, UNC3230 did not inhibit any of the other lipid kinases that regulate phosphoinositide levels, including phosphatidylinositol 4,5-bisphosphate 3-kinases (PIK3s, also known as PI3Ks) (Table S1; Figure S4 ). Note, PIP4K2C should not be confused with phosphatidylinositol 4-kinases (PI4Ks). PI4Ks generate PI(4)P from phosphatidylinositol and can be inhibited by Wortmannin and phenylarsine oxide (PAO) ( Figure S4 ) (Sorensen et al., 1998) .
Inhibition of PIP5K1C and/or PIP4K2C would be predicted to reduce PIP 2 levels, so we assessed how UNC3230 affected PIP 2 levels in DRG neurons by using the PIP 2 -specific antibody. We found that membrane PIP 2 levels were significantly reduced by $45% in DRG neurons treated with 100 nM UNC3230 ($2-fold above the IC 50 ) relative to vehicle controls ( Figures 6A  and 6B ). PI(4)P is present at 10-fold higher concentration over PI(5)P in cells (Delage et al., 2013) , making UNC3230 more likely to affect PIP 2 that is generated by PIP5K1C. In addition, we found that UNC3230 significantly reduced LPA-evoked calcium signaling in cultured DRG neurons relative to vehicle ( Figures 6C  and 6D ). Collectively, our data indicate that UNC3230 represents a pharmacological probe that can be used to inhibit two lipid kinases that directly generate PIP 2 . Moreover, our data suggest that UNC3230 blunts pronociceptive receptor signaling in DRG neurons in a manner that is analogous to Pip5k1c haploinsufficiency.
UNC3230 Has Antinociceptive Effects when Injected Intrathecally or into an Inflamed Hindpaw
Next, we monitored sensitivity in WT mice before and shortly after i.t. or intraperitoneal (i.p.) administration of UNC3230. We found that UNC3230 (2 nmol in 20% DMSO) significantly increased noxious heat-evoked paw withdrawal latency for 2 hr after i.t. injection ( Figure 7A ), indicating an antinociceptive effect. UNC3230 did not have an acute effect on mechanical sensitivity ( Figure 7B ) and did not exhibit antinociceptive activity when administered i.p. (Figure S5A ). This lack of activity via the i.p. route could reflect different pharmacokinetic properties following systemic versus localized (i.t. or into hindpaw, see below) drug delivery. To evaluate dose-dependence, we administered UNC3230 at 1, 2, and 3 nmol (i.t.). We did not observe antinociceptive activity at 1 nmol (in 20% DMSO) but observed antinociceptive activity at 2 nmol (in 20% DMSO) that was similar to 3 nmol (in 50% DMSO) ( Figure 7A and data not shown). In contrast, an inactive analog that is structurally similar to UNC3230 (by addition of a methyl group to the primary amide) did not exhibit thermal antinociceptive activity ( Figure S5B ), suggesting the antinociceptive activity of UNC3230 reflects ontarget engagement of PIP5K1C ( Figure S5B ). Lastly, UNC3230 (2 nmol, i.t.) did not affect performance in the rotarod assay ( Figure S5C ).
Given that UNC3230 blunted LPA-evoked signaling, and that LPA enduringly enhances thermal and mechanical sensitivity by activating LPA receptors over a brief 3 hr critical period (Ma et al., 2009) , we next evaluated the extent to which UNC3230 could reduce LPA-evoked thermal and mechanical hypersensitivity. We administered UNC3230 (2 nmol; i.t.; versus vehicle) then 1 hr later coinjected 1 nmol LPA with UNC3230 (2 nmol, i.t.; versus vehicle). UNC3230 significantly blunted thermal hyperalgesia and mechanical allodynia compared to vehicle (Figures 7C and 7D) . Next, we administered UNC3230 (2 nmol; i.t.) 2 hr before and 2 hr after injecting CFA into one hindpaw. We found that UNC3230 significantly blunted thermal hyperalgesia and mechanical allodynia in the CFA-inflamed hindpaw (relative to vehicle control) but did not affect thermal or mechanical sensitivity in the control (noninflamed) hindpaw over a multiday time course (Figures 7E and 7F ). To determine if UNC3230 had antinociceptive effects in animals with ongoing inflammation, we injected CFA into one hindpaw and then 48 hr later injected UNC3230 (2 nmol; i.t.). UNC3230 significantly reduced existing CFA-induced thermal hyperalgesia (relative to vehicle control) ( Figure 7G ). UNC3230 did not affect existing mechanical allodynia when administered following CFA inflammation (data not shown). Additionally, peripheral administration of UNC3230 (8 nmol, into the CFA-inflamed hindpaw), reduced thermal hyperalgesia ( Figure 7H ). Taken together, these data suggest UNC3230 could be used to block the initiation of chronic pain, with effects on hypersensitivity that are similar in magnitude to Pip5k1c haploinsufficiency, and can reduce established pain hypersensitivity.
DISCUSSION
Our study provides evidence that PIP5K1C generates at least half of all PIP 2 in DRG neurons and is a critical regulator of nociceptive signaling and sensitization, including thermal and mechanical hypersensitivity in models of neuropathic and inflammatory pain, two common forms of chronic pain in humans. Our conclusions are supported by experiments with Pip5k1c +/À mice and with a small molecule inhibitor of PIP5K1C. Pip5k1c haploinsufficiency reduced PIP 2 levels in adult DRG by $50% without affecting PIP 2 levels in adult brain or spinal cord (Figure 1K) , making it unlikely that the phenotypes we observed were due to Pip5k1c haploinsufficiency in other regions of the nervous system. Moreover, spinal delivery of UNC3230 recapitulated these antinociceptive phenotypes, suggesting that localized inhibition of PIP5K1C in adults (and not during development) is sufficient to reduce nociceptive sensitization.
With the possible exceptions of our intrathecal LPA experiment and intraplantar experiment ( Figures 4A, 4B , and 7H), in no cases was sensitization restored to baseline levels in Pip5k1c +/À mice or following UNC3230 administration. This could reflect the fact that GPCR signaling was reduced, but not eliminated, in neurons from Pip5k1c +/À mice and following UNC3230 treatment. Moreover, there are likely additional enzymes in DRG that generate PIP 2 and contribute to pronociceptive receptor signaling. In support of this possibility, PIP 2 levels were not reduced to zero in DRG from Pip5k1c À/À (embryonic) mice ( Figure 1H ). There are additional signaling pathways and cellular mechanisms that contribute to nociceptive sensitization (Basbaum et al., 2009; Gold and Gebhart, 2010 ) and some of One hour later, vehicle or 2 nmol UNC3230 was administered i.t. with 1 nmol LPA. n = 10 male mice per group. One-way ANOVA were used to assess treatment effect over the 7-day time course (black asterisks).
(E and F) Thermal (E) and mechanical (F) sensitivity of WT mice in the CFA model of inflammatory pain. Vehicle or 2 nmol UNC3230 were administered i.t. Two hours later, CFA was injected into one hindpaw of each animal. The other hindpaw was not inflamed and served as a control. Vehicle or 2 nmol UNC3230 was administered (i.t.) 2 hr after CFA injection. n = 10 male mice per group. One-way ANOVA were used to assess treatment effect over the 7-day time course (black asterisks).
(G and H) Thermal sensitivity of WT mice in the CFA model of inflammatory pain. CFA was injected into one hindpaw of each animal. The other hindpaw was not inflamed and served as a control.
(G) Two days post-CFA injection, vehicle or 2 nmol UNC3230 was administered i.t. n = 10 male mice per group. (H) One day post-CFA injection, vehicle or 8 nmol UNC3230 was administered into the inflamed hindpaw. n = 10 mice per group. (G) Oneway ANOVA was used to assess treatment effect in the noninflamed paw over the 5 hr time course following injection (gray asterisk). All data are mean ± SEM. *p < 0.05, **p < 0.005. (H) One-way ANOVA were used to assess treatment effect over the 7-day time course (black asterisks). See also Figure S5 .
these mechanisms are likely to be independent of Pip5k1c and PIP 2 . Intrathecal injections target DRG and spinal cord (Luo et al., 2005) . Our efforts to measure small and possibly localized changes in PIP 2 levels in DRG following intrathecal injection were unsuccessful (data not shown). Thus, we cannot rule out the possibility that UNC3230 affects nociceptive sensitization by inhibiting PIP5K1C in the DRG and/or spinal cord (PIP5K1C is expressed by spinal neurons but is not expressed by spinal microglial cells; Allen Brain Atlas and data not shown). However, given that UNC3230 had antinociceptive effects when injected intrathecally as well as peripherally into the hindpaw, our data suggest that central or peripheral inhibition of PIP5K1C, presumably in primary sensory neurons or their afferents, is sufficient to reduce nociceptive responses. Moreover, PIP 2 levels were reduced in DRG but not spinal cord or brain of Pip5k1c +/À mice, suggesting the antinociceptive phenotypes in Pip5k1c +/À mice were due to reduced activity of PIP5K1C in primary sensory neurons.
As for why PIP 2 levels were reduced in DRG of Pip5k1c
mice but not spinal cord or brain, we speculate this reflects a greater dependence on Pip5k1c in DRG relative to these other tissues. In support of this idea, PIP 2 levels were not reduced in the brain of Pip5k1c +/À mice ( Figure 1K ) (Volpicelli-Daley et al., 2010), but were reduced by 50% in the brain of embryonic Pip5k1c À/À mice (Volpicelli-Daley et al., 2010; Wang et al., 2007) . Thus, PIP 2 levels in the central nervous system appear to be insensitive to Pip5k1c haploinsufficiency. Additionally, PIP 2 levels were not reduced in the brain of embryonic Pip5k1a, Pip5k1b double knockout mice, suggesting other enzymes besides Pip5k1a, Pip5k1b, or Pip5k1c generate PIP 2 in the nervous system (Volpicelli-Daley et al., 2010) . This greater dependence on Pip5k1c in DRG makes this lipid kinase a particularly attractive target for analgesic drug development, as inhibition of PIP5K1C has the potential to lower PIP 2 levels in primary sensory neurons to a greater extent than in the brain.
PIP5K1C
Modulates Pronociceptive Receptor Signaling via a PIP 2 -Dependent Mechanism PIP 2 -dependence was supported by the fact that addition of PIP 2 rescued signaling deficits in Pip5k1c +/À neurons. Others similarly found that PIP 2 addition rescued histamine-evoked calcium responses in HeLa cells following Pip5k1c knockdown (Wang et al., 2004) . ATP-evoked calcium release from purinergic receptors was significantly blunted in Pip5k1c +/À lateral nonsensory cells (Rodriguez et al., 2012) , further indicating that Pip5k1c regulates receptor signaling. Furthermore, our data reveal that Pip5k1c haploinsufficiency eliminates GPCR-mediated sensitization of TRPV1 ( Figure 3C ).
Pip5k1c regulates many additional processes downstream of PIP 2 , including actin dynamics, synaptic vesicle release, and NMDA-induced AMPA receptor endocytosis (Rusinova et al., 2013; Tó th et al., 2012; Unoki et al., 2012; van den Bout and Divecha, 2009 ). We ruled out the possibility that neurotransmission was impaired between sensory neurons and spinal neurons in Pip5k1c +/À mice, making it unlikely that vesicle recycling deficits accounted for reduced behavioral sensitization. However, we cannot exclude the possibility that other mechanisms downstream of PIP 2 are impaired in Pip5k1c +/À mice. Future studies will be needed to assess the relative contribution of these downstream mechanisms to nociceptive deficits in Pip5k1c +/À mice.
PIP5K1C Is an Analgesic Drug Target
The antinociceptive phenotypes in Pip5k1c +/À mice motivated us to develop a high-throughput screen for PIP5K1C inhibitors. From this screen, we identified UNC3230, a compound that inhibited PIP5K1C in the nanomolar range and reduced receptor signaling and nociceptive sensitization analogous to Pip5k1c haploinsufficiency. While we evaluated the specificity of UNC3230 relative to a large panel of kinases, we cannot exclude the possibility that UNC3230 inhibits kinases that were not available for testing, including additional kinases that generate PIP 2 . Given that UNC3230 reduced PIP 2 levels in DRG and had antinociceptive activity in vivo, whereas an inactive close analog of UNC3230 did not have antinociceptive activity, these data suggest that UNC3230 has on-target biochemical effects. UNC3230 showed selectivity for PIP5K1C and PIP4K2C, two lipid kinases that directly generate PIP 2 . The DiscoveRx Selectivity Profile score for UNC3230 was 0.12 (on a scale from 0 to 1.0) (Karaman et al., 2008) . To put this value in context, of 38 kinase inhibitors (several of them FDA-approved) benchmarked in this assay at 3 mM (Karaman et al., 2008) , a majority (n = 22) were less selective than UNC3230. Our genetic and pharmacological data validate PIP5K1C as a therapeutic target for chronic pain; however, further optimization of hits from our high-throughput screen is warranted. For example, UNC3230 has a narrow efficacy window and low solubility in appropriate vehicles that limited our ability to perform dose-responses in vitro and in vivo. These shortcomings may be overcome through subsequent medicinal chemistry optimization, particularly given that PIP5K1C inhibitors could provide an alternative to opioid and nonsteroidal antiinflammatory analgesics. Moreover, PIP5K1C inhibitors will likely have uses that extend beyond the nociceptive system, such as to study how transient PIP5K1C inhibition affects other processes linked to PIP5K1C.
There are a number of additional enzymes that could affect PIP 2 levels in DRG neurons, including lipid kinases other than PIP5K1C, phosphatases and lipid transporters. Our current study suggests these additional enzymes represent attractive targets for analgesic drug development. In support of this idea, a functional-genomics study in Drosophila identified phospholipid signaling and lipid kinases as key regulators of heat nociception (Neely et al., 2012) . This study also found that Pip5k1a À/À mice (not Pip5k1c) displayed hypersensitivity to noxious heat and capsaicin. However, given that Pip5k1a is expressed at much lower levels in DRG ( Figure 1A ) and does not contribute to PIP 2 levels in the central nervous system (Volpicelli-Daley et al., 2010) , precisely how and where Pip5k1a regulates heat nociception in mice is unclear.
Human Implications
Humans carrying heterozygous null mutations in Pip5k1c (i.e., PIP5K1C +/À humans) develop normally and appear healthy (Narkis et al., 2007) . Because humans apparently can tolerate a lifelong reduction in PIP5K1C gene dosage, drugs that transiently inhibit PIP5K1C have the potential to be well-tolerated-particularly in adults-the age group that suffers most from chronic pain. The high-frequency hearing loss seen in Pip5k1c +/À mice is not likely to be an issue in humans because humans cannot hear above 20 kHz (Brant and Fozard, 1990) . In contrast, PIP5K1C
À/À humans develop lethal congenital contracture syndrome type 3, which is characterized by muscle atrophy, joint contractures, and death within 24 hr of birth (Narkis et al., 2007 Paolo et al., 2004) . All mice were backcrossed to C57BL/6 mice for at least ten generations.
Immunostaining
Lumbar DRG and spinal cord were dissected from adult (6-to 8-week-old) male mice and immunostained as previously described (McCoy et al., 2013; Zylka et al., 2008) .
ELISA PIP 2 Quantification PI(4,5)P 2 mass ELISA was purchased from Echelon Biosciences (K-4500) and performed according to the manufacturer's instructions with the following alterations. Lumbar DRG (L3-L5, bilateral), lumbar spinal cord, and cerebral cortex were dissected from adult male mice (6-to 8-week-old) and all DRG were dissected from embryos (E17.5-18.5). All tissue was frozen immediately on dry ice. Tissue was homogenized and sonicated prior to lipid extraction. DRG samples were diluted 1:40 and spinal cord and brain samples were diluted 1:200 prior to use in the ELISA assay. Bicinchoninic acid (BCA) protein determination assay (ThermoScientific, 23225) was completed for each sample following the manufacturer's instructions. Protein content for each sample was used for normalization.
Neuron Culture and Calcium Imaging
All DRG were dissected from 3-to 8-week-old male mice following decapitation and cultured as described (see Supplemental Experimental Procedures). Calcium imaging of dissociated neurons was completed as described previously using Fura 2-acetoxymethyl ester (2 mM; F1221, Invitrogen) (McCoy et al., 2013) .
Behavioral Assays
Pronociceptive ligands (4.1 mg LPA; 1.2 mg 17-PT PGE 2 , in 0.9% saline) were injected into the left hindpaw and the amount of time spent licking was measured for 5 min. Thermal and mechanical sensitivity were monitored before and 30 min after capsaicin (2 mg) injection. Thermal sensitivity was measured using a Plantar Test apparatus (IITC) to heat each hindpaw and the latency for hindpaw removal was recorded. One measurement was taken for each hindpaw to determine the withdrawal latency in seconds. The radiant heat source intensity was calibrated so that the average withdrawal latency for WT mice was $10 s. Cut off time was 20 s. Mechanical sensitivity was measured using an electronic von Frey apparatus (IITC) and a semiflexible tip. Three measurements for each hindpaw were taken and averaged to determine the withdrawal threshold in grams. For the restrained hot plate test, animals were restrained by scruffing and the right hindpaw was placed on a metal surface of the indicated noxious temperature. The latency for the animal to withdrawal (lift, shake, or jump) its hindpaw was recorded. Inflammatory (CFA) and neuropathic (LPA and spared nerve injury) models of chronic pain were performed as described previously (Ma et al., 2009; Shields et al., 2003; Zylka et al., 2008) . Intrathecal injections (5 ml) were performed in unanesthetized mice using the direct lumbar puncture method (Fairbanks, 2003) . UNC3230 was prepared at a final concentration of 0.4 mM (2 nmol per 5 ml) in 20% DMSO or 0.6 mM in 50% DMSO for intrathecal injections. UNC3230 was prepared at a final concentration of 0.4 mM in 20% DMSO for intraplantar injections (20 ml per hindpaw; 8 nmol total). For intraperitoneal injections, 5 mM UNC3230 was prepared in 90% corn oil and 10% ethanol and administered at 20 mg/kg.
Small Molecule Inhibitor Screen
N-terminal His 6 -tagged full-length (90 kDa) recombinant human PIP5K1C (Millipore 14-845) was incubated for 10 min in the presence or absence of small molecules in assay buffer (50 mM MOPS, 500 mM sodium cholate, 10 mM magnesium chloride, and 25 mM sodium chloride) in 384-well Nunc assay plates. Fluorescein conjugated substrate (PI(4)P; Cayman Chemical, 9000655) and ATP at the K m concentration for PIP5K1C (15 mM) were added to the assay plates and incubated for 40 min. Reactions were stopped using 90 mM EDTA. Fluorescein conjugated PIP 2 and remaining PI(4)P were separated and quantified using the LabChip EZ Reader II microfluidic mobility shift assay (PerkinElmer). Validation of the assay was performed in duplicate using the library of pharmacologically active compounds (LOPAC; Sigma), giving a r 2 value of 0.965. We used this assay to screen a focused kinase library ($5,000 compounds), which contained UNC3230.
Selectivity Screening
Two different assays were used to assess selectivity. ProfilerPro (PerkinElmer) was used to assess selectivity of UNC3230 on 48 kinases. For the ProfilerPro assay, UNC3230 was added to reaction-ready (384-well) assay plates (PerkinElmer) containing each of the 48 kinases in duplicate and incubated for 15 min. Matching fluorescent substrates for each kinase (also provided in reaction-ready 384-well plates) and ATP at the K m for each kinase were added then the plate was incubated for 90 min. Fluorescent substrates and products were separated and quantified using the LabChip EZ Reader II microfluidic mobility-shift assay (PerkinElmer). Data for this assay are reported as percent of control (product produced in the absence of UNC3230). The DiscoveRx KINOMEscan competitive binding assay was used to quantitatively measure interactions between UNC3230 and 100 different kinases. Briefly, UNC3230 and each DNA-tagged kinase were added simultaneously to 384-well plates containing immobilized ligands for each of the 100 kinases tested. Plates were incubated for 1 hr and the amount of kinase bound to the immobilized ligand was quantified using quantitative PCR (qPCR) and the associated DNA tag. Binding interactions were determined by the amount of kinase bound to the immobilized ligand. Competitive interactions between the kinase and UNC3230 would prevent binding of the kinase to the immobilized ligand. Data for this assay are reported as percent of control (binding of a control compound to the kinase).
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